英文名：Factive
通用名：甲磺酸吉米沙星
医疗保险：是
产品类别：化学药品
主要成分：每片含有甲磺酸吉米沙星320mg
产品性状：吉速星为白色或类白色薄膜包衣片，药片两面凹刻有320字样
适应症： 社区获得性肺炎慢性支气管炎急性发作急性细菌性鼻窦炎尿路感染(仅在墨西哥和南美地区(截止2011年))
【使用方法】
1. 本品可与食物同服或不与食物同服，完整吞服并饮用随意量的液体。
2. 本品的推荐剂量为每日320mg（1片）：
- 社区获得性肺炎-一次320mg（1片），一日一次，服用5-7天
- 慢性支气管炎急性发作-一次320mg（1片），一日一次，服用5天
- 急性细菌性鼻窦炎-一次320mg（1片），一日一次，服用5天
- 尿路感染：一次320mg（1片），一日一次，服用3天。
【健康信息】
已有超过350万患者证明了产品安全性。
对肝损伤患者和老年人——无需剂量的调整。
没有对血糖影响存在禁忌和注意事项。
建议肌酐清除率小于40ml/min的患者（肾功能损伤），必须调整给要方案，每24小时服用160mg。
最常见的不良反应报告为腹泻(3.7%), 头痛 (0.8%), 恶心 (2.4%), 皮疹(1.1%) 和腹痛(0.8%)。
本品对儿童、青少年（年龄未满18岁）、孕妇及哺乳期妇女的安全性与有效性尚未建立。
【规格】
3片/盒, 5片/盒, 7片/盒, 30片/盒
【贮藏】
室温保存, 密封容器
【有效期】
48个月
【生产企业】
企业名称：LG Life Sciences, Ltd.
Product Name
Factive (gemifloxacin mesylate)
Composition
Each oral tablet contains gemifloxacin mesylate equivalent to 320mg.
Indication
Community-acquired pneumonia (CAP)
Acute exacerbation of chronic bronchitis (AECB)
Acute bacterial sinusitis (ABS)
Uncomplicated urinary tract infection (uUTI)*
*In Mexico and South Aftrica
Dosage and Administration
Factive can be taken with or without food and should be swallowed whole with a liberal amount of liquid.
The recommended dose of factive is 320mg daily, as the following:
CAP – One 320mg tablet daily for 5 to 7 days
AECB, ABS – One 320mg tablet daily for 5 days
uUTI - One 320mg tablet daily for 3 days
How Supplied
FACTIVE is available as white to off-white, oval, film-coated tablets with breaklines and GE 320 debossed on both faces.
In packs of 3, 5, 7 and 30.
Storage Condition
Store at 25ºC (77ºF); excursions permitted to 15º ~ 30ºC (59º ~ 86ºF). Protect from light.
Shelf Life
48 months
Healthcare Information
Demonstrated safety in more than 3.5 million patients
Safe for patients with hepatically impairment or elderly – no dosage adjustments for mild to moderate impairment
No warning or precautions regarding disturbances in blood glucose
Recommended for patients with creatinine clearance < 40ml/min to take 160mg every 24h
The most frequently reported adverse events in clinical studies were diarrhea (3.7%), headache (0.8%), nausea (2.4%), rash (1.1%) and abdominal pain (0.8%)
The safety and effectiveness of gemifloxacin in children, adolescents (<18 years of age), pregnant women, and lactating women have not been established.